Clinical Trials
23 trialsNCT06377852 2026-06-05
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
American Society of Clinical Oncology
Phase 3 Recruiting
NCT06065748 2026-06-04
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Recruiting
NCT07174336 2026-06-04
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
Phase 3 Recruiting
NCT07492641 2026-06-03
KANDELA-302
BeOne Medicines
Phase 3 Recruiting
NCT07405164 2026-05-29
MK-6482-043
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04862663 2026-05-27
CAPItello-292
AstraZeneca
Phase 3 Recruiting
NCT03425838 2026-05-20
Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer
Borstkanker Onderzoek Groep
Phase 3 Active not recruiting
NCT04546009 2026-05-19
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06760637 2026-05-19
FourLight-3
Pfizer
Phase 3 Active not recruiting
NCT06757634 2026-05-18
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Celcuity Inc
Phase 3 Recruiting
NCT06380751 2026-05-15
EvoPAR-BR01
AstraZeneca
Phase 3 Recruiting
NCT02297438 2026-05-14
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
Pfizer
Phase 3 Completed
NCT03784014 2026-04-29
MULTISARC
Institut National de la Santé Et de la Recherche Médicale, France
Phase 3 Completed
NCT04964934 2026-04-21
SERENA-6
AstraZeneca
Phase 3 Active not recruiting
NCT03820830 2026-04-09
POLAR
ETOP IBCSG Partners Foundation
Phase 3 Active not recruiting
NCT02947685 2026-02-12
PATINA
Alliance Foundation Trials, LLC.
Phase 3 Active not recruiting
NCT02513394 2026-02-10
PALLAS
Alliance Foundation Trials, LLC.
Phase 3 Active not recruiting
NCT05501886 2026-02-10
VIKTORIA-1
Celcuity Inc
Phase 3 Active not recruiting
NCT05909397 2026-02-10
VERITAC-3
Pfizer
Phase 3 Active not recruiting
NCT03079011 2025-11-18
PADA-1
UNICANCER
Phase 3 Completed
NCT04711252 2025-10-14
SERENA-4
AstraZeneca
Phase 3 Active not recruiting
NCT04478266 2025-09-11
AMEERA-5
Sanofi
Phase 3 Terminated
NCT07061717 2025-07-11
Comparing Endocrine Therapy Combined With High-Dose Palbociclib and Hydroxychloroquine to Endocrine Therapy Combined With Standard-Dose Palbociclib for Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3 Not yet recruiting